Veru Inc. completed and exceeded its targeted enrollment of 200 patients for the Phase 2b PLATEAU clinical trial. The study evaluates oral enobosarm combined with semaglutide, a GLP-1 drug. It targets weight loss in obese patients aged 65 and older.
The trial aims to determine if enobosarm improves weight loss quality by preserving muscle mass and physical function while augmenting fat loss. This marks a key milestone for enobosarm as a potential next-generation combination therapy in the lucrative obesity market.
Veru expects to report interim analysis results from the PLATEAU study in the first quarter of 2027. Veru anticipates final topline data from the 68-week study in the fourth quarter of 2027.